Exsilio’s technology is based on naturally occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates.

The company uses predictive in silico modeling and wet lab-based experimentation to engineer such elements for precise insertion of therapeutic genes into safe harbor sites of disease-relevant cells. 

Because Exsilio’s medicines are encoded in mRNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent.